Aktienanalyse zu SIGA Technologies Inc (SIGA)SIGASIGA Technologies Inc

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $2.95, the RSI of 27.309 indicates that the stock is oversold, suggesting potential for a rebound. However, the forward P/E ratio of 2.8058 is low, indicating that the stock may be undervalued, but the recent performance shows a year-to-date change of -52.95%, which raises concerns about its stability. The main risk is the company's inconsistent revenue stream, as evidenced by a significant drop in net income in Q1 2026, where it reported a net loss of $3 million. Therefore, while there are signs of potential recovery, caution is advised before making a buy decision.